Asia-Pacific Pharma & Life Sciences Newsletter – March 2013

The PwC Pharma & Life Sciences experts are pleased to present you with the tenth issue of our Asia-Pacific pharmaceutical industry newsletter.

Our first Newsletter for the 2013 calendar year contains reports from covering various areas of interest to Pharmaceutical & Life Sciences companies across the region.

In our Compliance section we report on Australia’s upcoming disclosure regime in respect of the payments made to doctors.

Our Pricing section once more reports on many developments throughout Asia Pacific includes including Australia’s pricing and reimbursement environment, China’s latest price cuts, Japan’s price reductions for generics and on India’s new drug pricing policy.

Finally, in our Tax section, we outline the finalised retrospective changes to Transfer Pricing rules and General Anti-Avoidance Rules (GAAR) in Australia, look at further guidance on ‘beneficial owner’ status in China, review India’s new General Anti Avoidance Rules (GAAR), look at changes in Taiwan’s taxation of shares and securities and some new safe harbour provisions in Singapore.